Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7

We investigated the efficacy of a small molecule ASR-600, an analog of Urolithin A (Uro A), on blocking androgen receptor (AR) and its splice variant AR-variant 7 (AR-V7) signaling in castration-resistant prostate cancer (CRPC). ASR-600 effectively suppressed the growth of AR(+) CRPC cells by inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrasekaran, Balaji, Tyagi, Ashish, Saran, Uttara, Kolluru, Venkatesh, Baby, Becca V., Chirasani, Venkat R., Dokholyan, Nikolay V., Lin, Jyh M., Singh, Amandeep, Sharma, Arun K., Ankem, Murali K., Damodaran, Chendil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020188/
https://www.ncbi.nlm.nih.gov/pubmed/36937838
http://dx.doi.org/10.3389/fphar.2023.1137783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020188/
https://www.ncbi.nlm.nih.gov/pubmed/36937838
http://dx.doi.org/10.3389/fphar.2023.1137783

Ejemplares similares